According to recent publications, the stem cell signature of diffuse astrocytoma is quite different from the other two glioma subtypes, indicating that HOXA10 may be a potential biomarker for the identification of diffuse astrocytoma cells and validating the efficacy and accuracy of our prediction [62,63]. This evidence concerns the gene HOXA10 and central nervous system cancer.